NCT05313646已完成4 期
Safety, Immunogenicity, and Batch Consistency of a Single Dose of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Chinese Healthy Adults Aged 18 Years and Above: a Randomized, Double-blind, Parallel-controlled Clinical Trial
Jiangsu Province Centers for Disease Control and Prevention1 个研究点 分布在 1 个国家目标入组 1,050 人开始时间: 2021年3月8日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 1,050
- 试验地点
- 1
- 主要终点
- GMTs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination.
研究概览
简要总结
This is a randomized, double-blind, parallel-controlled, equivalence trial, for evaluation of safety and immunogenicity, and batch-to-batch consistency of a recombinant adenovirus type-5-vectored Covid-19 vaccine Convidecia in one shot schedule in Chinese healthy adults aged 18 years and above. In total 1050 healthy adults will be recruited in this study. Subjects in both cohort will be randomized stratified into two cohort by age(18~59 years and≥60 years) in a 1:1:1 ratio to receive one of three consecutive batches of Convidecia. The primary objective is to test the equivalence of the immune responses to three consecutive manufacturing lots of Convidecia in healthy adults. The secondary objectives were to evaluate the immunogenicity and safety of Convidecia for each lot and the pooled data of three lots)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
Participants and investigators will be kept blinded.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •healthy participants aged 18 years and above who have not received COVID-19 vaccine.
- •The subjects can provide with informed consent and sign informed consent form (ICF).
- •The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the follow-up of the study.
- •Axillary temperature ≤ 37.0℃.
- •negative IgM and IgG against SARS-CoV-2
- •with BMI between18.5 to 30.0
- •No history of epidemiological contact with COVID-2019
- •have not been to medium or high risk areas in the past 21 days and have no history of departure.
- •be determined to be healthy by medical history, physical examination and clinical examination and meet the requirements for immunization of this product.
- •Exclusion criteria:
- •Medical history or family history of convulsion, epilepsy, encephalopathy and psychosis.
- •Allergic to any component of the research vaccines, or a history of hypersensitivity or serious reactions to vaccination.
- •Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan in this study.
- •Suffering from acute febrile disease, infectious disease, or SARS infection history
- •Serious cardiovascular disease, such as arrhythmia, conduction block, myocardial infarction, severe hypertension, which cannot be controlled by medication (systolic blood pressure ≥180mmHg, diastolic blood pressure ≥110mmHg)
- •Have severe chronic diseases or unstable condition ( Grade 3 or higher as defined in the guidelines for the classification of adverse events in clinical trials for prophylactic vaccines), Such as diabetes, thyroid disease and so on.
- •Congenital or acquired angioedema / neuroedema.
- •had urticaria one year before this vaccination.
- •Asplenia or functional asplenia.
- •Thrombocytopenia or other clotting disorder (this may contraindicate intramuscular injection).
- •Faintng during acupuncture treatment
- •Received immunosuppressant therapy, antiallergic therapy, cytotoxic therapy, high dose inhaled corticosteroid over the past 6 months (excluding corticosteroid spray for allergic rhinitis, surface corticosteroid for acute non-complicated dermatitis, and corticosteroid with dose less than 20mg/ day)
- •Received blood products within 4 months before vaccination.
- •Received other investigational drugs within 1 month prior to receiving the investigational vaccines.
- •Received other live attenuated vaccines within 1 month prior to receiving the investigational vaccines.
- •Received subunit or inactivated vaccine within 14 days prior to receiving investigational vaccine.
- •Be receiving anti-tuberculosis treatment
- •Have the history of SARS-CoV-2 infection or COVID-19
- •Any medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the study protocol or affect the subjects' informed consent
排除标准
- 未提供
结局指标
主要结局
GMTs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination.
时间窗: On day 28 after vaccination
GMTs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination.
次要结局
- Propotion of participants with at least four-fold increase of post-vaccination antibody level against SARS-CoV-2 RBD-specific binding IgG compared to that at baseline on day 28 after vaccination.(On day 28 after vaccination)
- GMFIs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination.(On day 28 after vaccination)
- Incidence of adverse reactions within 28 days after vaccination.(Within 28 days after vaccination)
- Incidence of serious adverse events (SAE) within the 6 months after vaccination.(Within the 6 months after vaccination)
- Incidence of solicited adverse events within 7 days after vaccination.(Within 7 days after vaccination)
- Incidence of unsolicited adverse events within 28 days after vaccination.(Within 28 days after vaccination)
- GMTs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination stratified by neutralizing antibody levels against Ad5 at baseline.(On day 28 after vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Safety and Immunogenicity of a New Serum-free DTaP-IPVvero Combination VaccineActive ImmunizationNCT00655148Statens Serum Institut817
已完成
3 期
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B VaccineHealthyNCT01005407Dynavax Technologies Corporation2,452
已完成
1 期
Phase I Trial of Envafolimab for Healthy Male SubjectsHealthy MaleNCT058493113D Medicines (Sichuan) Co., Ltd.160
已完成
1 期
Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian AdultsMalaria,FalciparumMalariaNCT03420053Sanaria Inc.21
已完成
不适用
A Trial to Evaluate the Efficacy and Safety of Lactobacillus Plantarum DSM 33464 on Blood Lead Levels in ChildrenElevated Blood Lead LevelsNCT04891666Novozymes A/S66